Brief: Aileron Therapeutics Regains Compliance With Nasdaq Listing Requirements
30/11/2022 12:14
Nov 30 (Reuters) - Aileron Therapeutics Inc ALRN.O :
* AILERON THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ
LISTING
REQUIREMENTS
Source text for Eikon: ID:nGNX2Lz96p
Further company coverage: ALRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering